Unknown PHASE2 INTERVENTIONAL 2-arm NCT04189055

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL)

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. A Proof-of-concept Study

Sponsor: Hôpital Franco-Britannique-Fondation Cognacq-Jay

Conditions Cancer Colorectal

Interventions Cetuximab Irinotecan

Updated 10 times since 2020 Last updated: Jun 9, 2023 Started: Jan 7, 2020 Primary completion: Apr 30, 2024 Completion: Jul 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04189055, this PHASE2 trial focuses on Cancer Colorectal and remains ongoing. Sponsored by Hôpital Franco-Britannique-Fondation Cognacq-Jay, it has been updated 10 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Jul 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jul 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Jul 2023 — Apr 2024 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Sep 2021 — Jul 2023 [monthly]

Recruiting PHASE2
Mar 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2020 — Feb 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hôpital Franco-Britannique-Fondation Cognacq-Jay

Data source: Hôpital Franco-Britannique-Fondation Cognacq-Jay

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Levallois-Perret, France